At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Nov 13, 2026 at 07:00 ET
BioCryst presented two real-world studies at ACAAI 2026 showing that ORLADEYO (berotralstat) reduces hospitalizations and emergency department visits in HAE patients, both in treatment-naïve initiators and in patients switching from another prophylactic therapy. The data support ORLADEYO's clinical and economic profile but are not a regulatory or commercial catalyst.
- ORLADEYO is the first and only targeted oral prophylactic therapy for HAE in patients aged 2 and older.
- Study 1 (n=78): Patients switching to ORLADEYO from another LTP saw a 30% reduction in overall angioedema-related visits (p=0.039) and a 30% reduction in outpatient/ED visits (p=0.040).
- Study 2 (n=128 ORLADEYO, n=236 lanadelumab, n=95 SC-pdC1-INH): All cohorts had statistically significant reductions in ED visits; ORLADEYO showed a 53% reduction in all-cause hospitalizations and a 61% reduction in angioedema-related ED visits.
- No statistically significant differences in magnitude of reductions were observed between ORLADEYO and lanadelumab or SC-pdC1-INH.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access